000			02246 a2200649 4500
005			20250515135452.0
264		0	_c20081229
008			200812s 0 0 eng d
022			_a1532-1967
024	7		_a10.1016/j.ctrv.2008.07.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aMaluf, Fernando Cotait
245	0	0	_aExploring the role of novel agents in the treatment of renal cell carcinoma. _h[electronic resource]
260			_bCancer treatment reviews _cDec 2008
300			_a750-60 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBenzenesulfonates _xadverse effects
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aDrug Delivery Systems
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIndoles _xadverse effects
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Staging
650	0	4	_aNephrectomy _xmethods
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aPrognosis
650	0	4	_aPyridines _xadverse effects
650	0	4	_aPyrroles _xadverse effects
650	0	4	_aSirolimus _xadverse effects
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
700	1		_aFernandes, Gustavo dos Santos
700	1		_aKann, Ariel Galapo
700	1		_aAguilar-Ponce, José Luis
700	1		_ade la Garza, Jaime
700	1		_aBuzaid, Antonio Carlos
773	0		_tCancer treatment reviews _gvol. 34 _gno. 8 _gp. 750-60
856	4	0	_uhttps://doi.org/10.1016/j.ctrv.2008.07.002 _zAvailable from publisher's website
999			_c18269475 _d18269475